Table 1 The characteristics of primary ectopic breast carcinoma of the vulva
Ref. | Year | Age | Size (cm) operation | Adjuvant therapy | Histology | ER | PR | Her2 | LN | Status | Follow-up (months) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Greene [12] | 1935 | 59 | 20 | None | None | Adenocarcinoma | * | * | * | * | Dead | 1 |
Hendrix [13] | 1956 | 58 | 3 | Vulvectomy | None | Adenocarcinoma | * | * | * | * | Dead | 4 |
Guerry [14] | 1976 | 62 | 1.5 | Partial | None | Ductal carcinoma | * | * | * | * | Dead | 24 |
Cho [15] | 1985 | 70 | 4 | Hemi-vulvectomy + LND | Tamoxifen | Adenocarcinoma | (+) | (+) | * | 2/9 | DF | 24 |
Simon [16] | 1988 | 60 | 2 | Vulvectomy + LND1 | CT + tamoxifen | Adenocarcinoma | (+) | (+) | * | 3/11 | Dead | 27 |
Rose [17] | 1990 | 68 | 3.5 | Vulvectomy | RT + tamoxifen | Ductal carcinoma | (+) | (−) | * | 1/15 | * | * |
Bonito [18] | 1992 | 46 | 1.5 | Vulvectomy + LND | None | * | * | * | * | 11/13 | DF | 4 |
Bailey [19] | 1993 | 65 | 3 | Vulvectomy + LND | Tamoxifen | Ductal carcinoma | (+) | (+) | * | 2/20 | DF | 12 |
Levin [20] | 1994 | 62 | 2.5 | Partial + LND | Tamoxifen | Adenocarcinoma | (+) | (−) | (+) | 4/11 | DF | 24 |
Kennedy [21] | 1997 | 71 | 5 | Vulvectomy + LND | CT + RT | * | (−) | (−) | * | 9/9 | DF | 15 |
Irvin [22] | 1998 | 64 | 3 | Partial + LND | CT + RT-F tamoxifen | Adenocarcinoma | (+) | (+) | * | 1/14 | DF | 4 |
Gorisek [23] | 2000 | 81 | 3 | Partial | Tamoxifen | Adenocarcinoma | (+) | (+) | * | DF | 19 | |
Neumann [24] 2000 | 60 | 3 | Hemi-vulvectomy + LND | CT + RT + tamoxifen | ILC | (+) | (+) | * | 21/21 | DF | 20 | |
Piura [25] | 2002 | 69 | 3 | Vulvectomy + LND | CT + tamoxifen | Adenocarcinoma | (+) | (+) | * | 7/15 | DF | 14 |
Chung [26] | 2002 | 47 | 2 | Vulvectomy | None | Mucinous | (+) | (+) | (−) | * | DF | 36 |
Yin [27] | 2003 | 84 | 5 | Partial + LND | None | Mucinous | (+) | (+) | (−) | 1/11 | DF | 9 |
Lopes [28] | 2006 | 44 | 2 | Partial + LND | CT + tamoxifen | Mucinous | (+) | * | (−) | 2/13 | * | * |
Fracchioli [29] 2006 | 57 | 1 | Vulvectomy + LND | CT + tamoxifen | Adenocarcinoma | (−) | * | * | 7/7 | Rec | 36 | |
North [4] | 2006 | 49 | 1.5 | Partial + LND | CT + tamoxifen | Ductal carcinoma | (+) | (+) | (−) | 5/7 | * | * |
Martinez [10] | 2007 | 49 | 3.5 | Partial + SLNB—LND | Tamoxifen | Ductal carcinoma | (+) | (+) | * | 0/14 | * | * |
Naseer [30] | 2011 | 57 | 1.5 | Partial + LND | CT + aromatase | Ductal carcinoma | (+) | (+) | (−) | 3/13 | * | * |
Diniz [2] | 2012 | 82 | 2 | Partial | RT + letrozole | IDC | (+) | (+) | * | * | DF | 48 |
McMaster [31] 2013 | 60 | 3 | Partial | RT | Ductal carcinoma | (+) | * | * | * | * | * | |
Bogani [9] | 2013 | 71 | 4 | Vulvectomy + SLNB—LND | CT + tamoxifen | Ductal carcinoma | (+) | (+) | * | 1/8 | DF | 24 |
Lamb [5] | 2013 | 59 | 1 | Partial + LND | Tamoxifen | Adenocarcinoma | (+) | (+) | (−) | * | * | * |
James [7] | 2015 | 62 | 1.3 | Partial | CT + RT | IDC | (+) | (+) | (−) | * | Rec | 13 |
Present case | 2016 | 72 | 1.5 | Partial + SLNB | Aromatase | IDC | (+) | (+) | (−) | 0/1 | DF | 6 |